Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00237614
Status:
COMPLETED
Last Update Posted:
2006-07-18
First Post:
2005-10-07
Brief Title:
Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction
Sponsor:
University of Milan
Organization:
University of Milan
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2005-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with acute myocardial infarction undergoing primary angioplasty are at high risk for renal injury due to the toxic effect of contrast agents Patients developing renal dysfunction after primary angioplasty have worse outcome To investigate the role of the antioxidant N-acetylcysteine NAC in preventing renal injury in angioplasty we randomized 352 consecutive patients undergoing primary angioplasty into three groups the first group received NAC at standard dose NAC group 600 mg iv bolus before primary angioplasty followed by oral 600 mg twice daily for the following 48 hours n115 the second group received NAC at double dose DD-NAC group 1200 mg iv bolus and oral 1200 mg twice daily for 48 hours n118 and the last group received placebo controls n119
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None